NeuroOne Medical Technologies Corporation (NMTC) is a pioneering company that focuses on designing, developing, and commercializing transformative neurosurgical technologies. The firm specializes in combining aspects of both medicine and technology to carve out innovative solutions for patients suffering from neurological disorders. Established initially in Minnesota, USA, NMTC has been operating to provide technological answers to some of the most challenging medical issues in the neurological field.
The vision of NeuroOne Medical Technologies Corporation is to develop and market breakthrough medical tools that can offer value-added and sophisticated surgical solutions to neurosurgeons, neurologists, and patients worldwide. Behind the commitment to this vision is a knowledge-driven approach, which sets them apart as they continually strive to refine and innovate in the arena of medical technology. They are continually investing in research and development to push the boundaries of what can be achieved in this field.
The company's products are primarily geared towards improving neurosurgical diagnostics, reducing patient discomfort, speeding up recovery times, and diminishing the need for extraneous medical procedures. Their product portfolio includes a series of cortical electrodes designed for both invasive diagnosis and treatment.
One of their pioneering solutions is the Evo™ sEEG Electrode, which is a thin film, minimally invasive device used in Stereo EEG procedures to identify seizure activity in the brain. Its unique design has potential benefits that include decreased operating time, post-implantation headaches, and hospital length of stay.
Naturally, the work carried out by NMTC requires consistent interaction with the United States Food and Drug Administration (FDA). The Evo™ sEEG Electrode, for instance, is FDA cleared in the U.S. Thus, the company often has to navigate the regulatory landscape, which involves meeting safety standards and proving the efficacy of their products in the medical field.
To finance its operations and research, NMTC funds its projects through strategic partnerships, capital investment, and listing on the stock exchange. Being a publicly traded company under the ticker NMTC, it offers stakeholders a chance to partake in their pioneering journey.
Looking towards the future, NeuroOne Medical Technologies Corporation aims to innovate and redefine the landscape of neurosurgical technology. They seek to leverage their vast knowledge, research findings, and industry insights to develop advanced medical solutions for the benefit of clinicians and patients alike, with the end goal of improving the standard of care in the neurological field.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
NeuroOne Medical Technologies announced the publication of initial clinical results for its OneRF Trigeminal Nerve Ablation System. A retrospective study of 15 patients with medically refractory trigeminal neuralgia showed that 14 patients were immediately pain-free, with the remaining patient becoming pain-free within a week. The multi-contact probe technology allowed mapping and treatment of multiple nerve distributions without repositioning, leading to favorable pain outcomes at a mean six-month follow-up for all patients.
NeuroOne Medical Technologies Corporation announced the peer-reviewed publication of initial clinical results for its OneRF® Trigeminal Nerve Ablation System. The study, published in Pain Management, reported immediate pain freedom in 14 of 15 patients with medically refractory trigeminal neuralgia, with all patients achieving favorable pain outcomes at a mean six-month follow-up. The multi-contact probe technology allowed for mapping and treatment of trigeminal nerve distributions without repeated probe repositioning, suggesting potential benefits in procedure time and patient comfort.
NeuroOne Medical Technologies Corporation has announced its first pharmaceutical industry purchase order for the StereoCED™ Drug Delivery Platform. This platform will support a preclinical animal research program for a Tier 1 global pharmaceutical company, leveraging its unique combination of targeted intracranial drug delivery and electrophysiological recording capabilities. This milestone is a significant step towards potential long-term collaborations and establishing StereoCED™ as a preferred drug delivery platform in the pharmaceutical industry.
NeuroOne Medical Technologies (NASDAQ:NMTC) reported preliminary fiscal fourth-quarter 2026 product revenue of $3.8 million, a 38.4% year-over-year increase, and full-year revenue of $10.5 million, hitting the top of its guidance. The company also announced securing its largest purchase order ever, valued at $4.5 million, with remaining shipments scheduled for fiscal first and second quarters of 2027. These figures are unaudited and subject to final accounting adjustments.